吡格列酮对糖调节受损、初发2型糖尿病患者胰岛素敏感性和血清同型半胱氨酸的影响  

The effect of pioglitazone treatment on homocysteine and insulin sensitivity in patient with T2DM and IGR

作　　者：徐伟[1] 洪兵[1] 徐晓文[1] 胡文[1] 柏凤[1] 赵荣芳[1] 俞伟男[1] 

机构地区：[1]徐州医学院附属淮安市第二人民医院内分泌科,223002

出　　处：《中国实用医药》2008年第23期22-23,共2页China Practical Medicine

摘　　要：目的探讨吡格列酮对糖调节受损、初发2型糖尿病患者胰岛素敏感性、血脂和血清同型半胱氨酸的影响。方法随机选取糖调节受损、初发2型糖尿病患者118例,糖调节受损患者58例,初发2型糖尿病患者60例。使用吡格列酮治疗12周,观察治疗前后胰岛素抵抗指数(Insulin Resistance Index,HOMA-IR)、血脂水平、血清同型半胱氨酸等指标的变化。结果吡格列酮治疗12周后HOMA-IR和血清同型半胱氨酸较治疗前降低(P<0.05),HDL-C升高(P<0.01)。结论吡格列酮能降低糖调节受损及初发2型糖尿病患者的血清同型半胱氨酸水平,改善胰岛素抵抗及血脂代谢。Objective To investigate the effect of pioglitazone on the levels of homocysteine, plasma lipids and the HOMA-IR in patients with impaired glucose regulation or newly diagnosed type 2 diabetes. Methods To recruit 118 patients with impaired glucose regulation （IGR） group and type 2 diabetic mellitus （T2DM）. The patients were treated with pioglitazone （15 mg/d） for 12 weeks without a change in previous medications. Levels of plasma lipids, fasting plasma glucose （ FPG）, insulin, hemoglobinA1c （HbA1C）, and homocysteine were measured. To compare the treatment effects between IGR group and T2DM group after 12 weeks＇ treatment. Results After pioglitazone for 12 weeks, homocysteine, the HOMA-IR in patients were lower than before, HDL-C were increased. Conclusion Pioglitazone can improve the insulin resistance and lipid metabolism in IGR and T2DM patients by reducing homocysteine.

关 键 词：糖调节受损 2型糖尿病 吡格列酮 同型半胱氨酸 

分 类 号：R587.1[医药卫生—内分泌]